HIV
Gilead’s next-generation HIV drug to be FDA assessed
April 8, 2015Research and Development, Sales and Marketing F/TAF, FDA, Gilead, HIV, Tenofovir Alafenamide, emtricitabine
Gilead Sciences has filed its second new drug application for a new combination HIV treatment with the FDA.The California-based company …
Merck puts HIV drug in shared patent pool
February 24, 2015Research and Development, Sales and Marketing AbbVie, Gilead, HIV, Merck, Raltegravir, Roche, isentress
Merck is teaming up with the Medicines Patent Pool (MPP) to license its paediatric HIV treatment in developing countries. The …
Pharma’s reputation ‘is worsening among patients’
February 10, 2015Medical Communications, Research and Development, Sales and Marketing HIV, ViiV Healthcare, patientview, pharma, reputation, transparency
Only around four in ten patients believe pharma has a good reputation and many companies are failing to win patient …
GSK blames respiratory woes as sales drop
February 5, 2015Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales
GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …
Gilead and Strides partner in HIV
January 21, 2015Research and Development, Sales and Marketing Cipla, FDA, Gilead, HIV, Ranbaxy, Tenofovir Alafenamide, WHO, strides, taf
Gilead is partnering with India-based pharma firm Strides Arcolab in a licensing agreement to manufacture and distribute an HIV treatment …
AbbVie Hep C combo pill ready for Europe
January 16, 2015Medical Communications AbbVie, Exviera, FDA, HIV, Viekira Pak, Viekirax, harvoni, hep C, sovaldi
The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …
New Lyrica formulation effective in trials
December 19, 2014Sales and Marketing HIV, Lyrica, Pfizer, pain, pregabalin, shingles
Pfizer has reported positive Phase III results for a new formulation of its painkiller Lyrica. In the study, a controlled-release …
Janssen launches HIV combination pill
December 17, 2014Research and Development, Sales and Marketing BMS, Gilead, HIV, Janssen, NHS, NICE, rezolsta, tybost
Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …
GSK mulls $27 billion ViiV sell-off
October 23, 2014Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV
After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …
More action needed on antibiotic resistance
July 25, 2014Medical Communications, Research and Development, Sales and Marketing AMR, Antibiotics, AstraZeneca, GSK, HIV, MRC, WHO, walsh
Pharma and governments need to put their heads together urgently in order to tackle the threat of antimicrobial resistance (AMR), …
Sovaldi scores in HIV patients
July 21, 2014Sales and Marketing Gilead, HIV, JAMA, hep C, hepatitis C, sovaldi
Patients with HIV and hepatitis C virus (HCV) have responded well to a combination of Gilead Sciences’ Sovaldi and ribavirin …
Twitter useful for tracking HIV outbreaks
March 5, 2014Medical Communications, Sales and Marketing AIDS, HIV, Twitter, digital, flu, ucla, virus, wells
A study by UCLA researchers has shown that Twitter and social media can be used as a practical real-time tool …
AbbVie ‘pleased’ with first year
February 3, 2014Sales and Marketing AbbVie, Abbott, CLL, EMA, HIV, Humira
Rheumatoid arthritis treatment Humira – as expected – has driven AbbVie in its first year as a standalone company, accounting …
BMS abandons hep C, diabetes and neuroscience
November 11, 2013Sales and Marketing BMS, HIV, diabetes, hep C
Bristol-Myers Squibb is admitting defeat in hepatitis C, diabetes and neuroscience and will abandon research in these areas in a …
Roche allows Valcyte access
August 5, 2013Sales and Marketing HIV, Roche, valcyte
Roche has signed a deal with a United Nations initiative to open up access to an oral drug which is …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
